Susquehanna International Group, LLP Day One Biopharmaceuticals, Inc. Put Options Transaction History

Susquehanna International Group, LLP

9 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	SELL	$12.72 - $16.03 $156,456 - $197,169	-12,300 Reduced 29.36%	29,600 $412,000
Q2 2024 Aug 15, 2024	BUY	$12.03 - $17.69 $132,330 - $194,590	11,000 Added 35.6%	41,900 $577,000
Q1 2024 May 07, 2024	BUY	$13.56 - $17.46 $174,924 - $225,234	12,900 Added 71.67%	30,900 $510,000
Q4 2023 Feb 14, 2024	SELL	$9.68 - $15.37 $25,168 - $39,962	-2,600 Reduced 12.62%	18,000 $262,000
Q3 2023 Nov 14, 2023	SELL	$11.22 - $14.86 $186,252 - $246,676	-16,600 Reduced 44.62%	20,600 $252,000
Q2 2023 Aug 11, 2023	BUY	$11.74 - $14.47 $264,150 - $325,575	22,500 Added 153.06%	37,200 $444,000
Q1 2023 May 16, 2023	SELL	$12.75 - $23.41 $100,725 - $184,939	-7,900 Reduced 34.96%	14,700 $196,000
Q4 2022 Feb 14, 2023	BUY	$18.77 - $22.0 $225,240 - $264,000	12,000 Added 113.21%	22,600 $486,000
Q3 2022 Nov 14, 2022	SELL	$16.44 - $26.57 $414,288 - $669,564	-25,200 Reduced 70.39%	10,600 $212,000

178

84M

144K

218K

Ticker DAWN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 73,461,104
Market Cap $978M
Description
Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric pa...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.